Bristol-Myers Squibb revenue and financials
$59.59Change from previous close: +1.33%Absolute change: +$0.78
In the fiscal year ended December 2025, Bristol-Myers Squibb reported revenue of $48.19B (−0.22% year over year). Net income was $7.05B, a net margin of 14.6%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −0.22%
- 2025 vs 2024
- Net margin
- 14.6%
- 2024: -18.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 12,973 | 11,489 | 12,502 | 12,222 | 12,269 | 11,201 | 12,342 | 11,892 | 12,201 | 11,865 | 11,477 | 10,966 |
| Cost of revenue | 3,711 | 3,408 | 3,507 | 3,312 | 3,356 | 3,018 | 3,212 | 2,856 | 2,971 | 2,910 | 2,707 | 2,490 |
| Gross profit | 9,262 | 8,081 | 8,995 | 8,910 | 8,913 | 8,183 | 9,130 | 9,036 | 9,230 | 8,955 | 8,770 | 8,476 |
| Selling, general and administrative | 1,824 | 1,610 | 2,087 | 1,788 | 1,689 | 1,581 | 1,852 | 2,080 | 1,921 | 1,968 | 2,064 | 1,938 |
| Research and development | 2,536 | 2,238 | 2,561 | 2,433 | 2,262 | 2,236 | 2,788 | 2,353 | 2,295 | 2,346 | 2,476 | 2,178 |
| Operating income | 4,465 | 3,796 | 3,521 | 3,858 | 4,132 | 3,536 | 2,797 | 2,197 | 2,598 | 2,284 | 1,952 | 2,104 |
| EBIT | 4,465 | 3,796 | 3,521 | 3,858 | 4,132 | 3,536 | 2,797 | 2,197 | 2,598 | 2,284 | 1,952 | 2,104 |
| EBITDA | 5,076 | 4,407 | 4,545 | 4,908 | 5,122 | 4,549 | 4,646 | 4,841 | 5,182 | 4,782 | 4,401 | 4,576 |
| Interest expense | 403 | 406 | 432 | 482 | 485 | 493 | 496 | 509 | 525 | 428 | 318 | 280 |
| Pre-tax income | 4,086 | 3,239 | 1,470 | 3,114 | 1,772 | 2,971 | 175 | 1,676 | 1,286 | -11,516 | 1,674 | 2,137 |
| Income tax | 770 | 561 | 384 | 919 | 460 | 509 | 99.0 | 461 | -398 | 392 | -88.0 | 203 |
| Net income | 3,317 | 2,677 | 1,087 | 2,201 | 1,310 | 2,456 | 72.0 | 1,211 | 1,680 | -11,911 | 1,762 | 1,928 |
| Net income to common shareholders | 3,317 | 2,677 | 1,087 | 2,201 | 1,310 | 2,456 | 72.0 | 1,211 | 1,680 | -11,911 | 1,762 | 1,928 |
| Basic EPS | 1.62 | 1.31 | 0.53 | 1.08 | 0.64 | 1.21 | 0.04 | 0.60 | 0.83 | -5.89 | 0.87 | 0.94 |
| Diluted EPS | 1.62 | 1.31 | 0.53 | 1.08 | 0.64 | 1.20 | 0.04 | 0.60 | 0.83 | -5.89 | 0.87 | 0.93 |
| Average shares (basic) | 2,042 | 2,038 | 2,036 | 2,036 | 2,035 | 2,031 | 2,029 | 2,028 | 2,027 | 2,023 | 2,027 | 2,057 |
| Average shares (diluted) | 2,048 | 2,047 | 2,041 | 2,039 | 2,038 | 2,040 | 2,037 | 2,031 | 2,029 | 2,023 | 2,033 | 2,064 |
| Dividend per share | 0.63 | 0.63 | 0.63 | 0.62 | 0.62 | 0.62 | 0.62 | 0.60 | 0.60 | 0.60 | 0.60 | 0.57 |
